290 related articles for article (PubMed ID: 17520565)
21. Oral phosphate binders.
Hutchison AJ
Kidney Int; 2009 May; 75(9):906-14. PubMed ID: 19279554
[TBL] [Abstract][Full Text] [Related]
22. Lanthanum carbonate--a first line phosphate binder?
de Freitas D; Donne RL; Hutchison AJ
Semin Dial; 2007; 20(4):325-8. PubMed ID: 17635822
[TBL] [Abstract][Full Text] [Related]
23. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
24. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
25. Slowing the progression of vascular calcification in hemodialysis.
Chertow GM
J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
27. Pharmacology of the phosphate binder, lanthanum carbonate.
Damment SJ
Ren Fail; 2011; 33(2):217-24. PubMed ID: 21332344
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
29. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
30. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
31. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
32. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Hanba Y; Masumoto A; Moribata M; Shigemathu T
Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
[TBL] [Abstract][Full Text] [Related]
33. The use of phosphate binders: data from contributors to the European Practice Database.
Elseviers M; De Vos JY
J Ren Care; 2009 Mar; 35 Suppl 1():14-8. PubMed ID: 19222726
[TBL] [Abstract][Full Text] [Related]
34. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
35. [New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Bover J; Ortiz-Herbener F; Ballarín J; Andrés E; Barceló P
Nefrologia; 2005; 25 Suppl 2():100-8. PubMed ID: 16050412
[TBL] [Abstract][Full Text] [Related]
36. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
37. [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].
Sesso R; Ferraz MB
Rev Assoc Med Bras (1992); 2003; 49(1):103-8. PubMed ID: 12724821
[TBL] [Abstract][Full Text] [Related]
38. Control of hyperphosphatemia among patients with ESRD.
Coladonato JA
J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
[TBL] [Abstract][Full Text] [Related]
39. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
Curran MP; Robinson DM
Drugs; 2009 Nov; 69(16):2329-49. PubMed ID: 19852531
[TBL] [Abstract][Full Text] [Related]
40. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]